Faron Pharmaceuticals has announced that it has initiated the Phase 2 part of the BEXMAB study for its drug bexmarilimab. The study will focus on patients with hypomethylating agents (HMAs)-refractory or relapsed myelodysplastic syndromes (MDS). The Phase 2 part of the study will enroll 32 patients with HMA-failed MDS and will randomize them between two recommended doses of bexmarilimab. The data from the first 20 patients will be reviewed to determine the exposure benefit for the two selected dose levels. Faron intends to discuss a potential registrational study plan with the FDA after final dosing is selected. The Phase 1 part of the study showed promising results, with a 50% remission rate and an overall response rate of 80% among previously failed HMA MDS patients. The drug was well-tolerated at all tested dose levels. Faron expects to open additional sites in the U.S. and Europe to increase recruitment speed.